ABC294640

RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Retrieved on: 
Tuesday, October 18, 2022
U.S. Securities and Exchange Commission, Helicobacter pylori, IBS-D, SEC, Attention, Annual report, ABC294640, Diarrhea, Cholangiocarcinoma, Patient, Crohn's disease, Security (finance), Gastritis, Nasdaq, NTM, Gastroenteritis, Cancer, Private Securities Litigation Reform Act, ADSS, Notice, American depositary receipt, Company, Opioid, Intention, Patent, Safety, Prostate cancer, Letter, TEL, Intellectual property, Forward-looking statement, Calendar, Redhill, COVID-19, Compliance, Risk, Auction, Pharmaceutical industry

The Nasdaq letter is only a notification of deficiency and has no immediate effect on the listing or trading of the Company's ADSs.

Key Points: 
  • The Nasdaq letter is only a notification of deficiency and has no immediate effect on the listing or trading of the Company's ADSs.
  • RedHill's ADSs will continue to trade on the Nasdaq Global Market, and the Company's operations are not affected by the receipt of the Notice.
  • RedHill intends to monitor the closing bid price of its ADSs and may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement.
  • RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases.

RedHill Biopharma to Host First Quarter 2022 Financial Results and Operational Highlights Webcast on June 23, 2022

Retrieved on: 
Friday, June 17, 2022
Webcast, Security (finance), Gastroenteritis, IBS-D, COVID-19, Prostate cancer, Annual report, Feedback, Genta (company), Company, Cholangiocarcinoma, U.S. Securities and Exchange Commission, ABC294640, Cancer, Research, Forward-looking statement, Private Securities Litigation Reform Act, Helicobacter pylori, TEL, Vii, Marketing, EDT, Opioid, Authorization, Diarrhea, Gastritis, SEC, Ix, Redhill, Nasdaq, Patient, Xi, NTM, Risk, Crohn's disease, Online gambling, Pharmaceutical industry, Naloxegol

TEL AVIV, Israel and RALEIGH, N.C., June 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its first quarter 2022 financial results and operational highlights on Thursday, June 23, 2022.

Key Points: 
  • TEL AVIV, Israel and RALEIGH, N.C., June 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its first quarter 2022 financial results and operational highlights on Thursday, June 23, 2022.
  • The Company will host a conference call and webcast on Thursday, June 23, 2022, at 8:30 a.m. EDT, during which it will present key highlights for the first quarter of 2022.
  • The webcast including slides will be broadcast live on the Company's website, https://ir.redhillbio.com/events ,and will be available for replay for 30 days.
  • RedHill Biopharma Ltd. (Nasdaq: RDHL ) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases.

RedHill Reports Potent Inhibition of Omicron with Oral COVID-19 Drug Candidate Opaganib In Vitro

Retrieved on: 
Monday, April 11, 2022
Private Securities Litigation Reform Act, Cholangiocarcinoma, Diarrhea, Culture, Research, SEC, School, Public health, Vii, Prostate cancer, Nasdaq, Opaganib, Annual report, Gastritis, Pneumonia, Security (finance), Crohn's disease, Population, Helicobacter pylori, Redhill, Marketing, Risk, XE, Delta, Naloxegol, Opioid, Senior, Xi, TNF, Ix, U.S. Securities and Exchange Commission, Genta (company), University, WHO, Forward-looking statement, Mortality, ABC294640, Open University of Hong Kong, National Institute, Severe acute respiratory syndrome coronavirus 2, Gastroenteritis, Review, Feedback, IL-6, Patient, Company, IBS-D, Nature, Cancer, RNA, Immunology, Center, Orphan drug, NTM, MedRxiv, Bronchoalveolar lavage, COVID-19, TEL, Authorization, VP, R, Pharmaceutical industry, Vaccine, Omicron, Infection

TEL AVIV, Israel and RALEIGH, N.C., April 11, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced study results in which opaganib (ABC294640)1, a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability. Based on the new and previously announced data, opaganib's unique human host-targeted, dual antiviral and anti-inflammatory suggested mechanism is expected to act independently of viral spike protein mutations and remain effective against Omicron sub-variants BA.2, XE and other emerging and future variants.

Key Points: 
  • Opaganib was studied in a global Phase 2/3 study in hospitalized patients with severe COVID-19 pneumonia (NCT04467840).
  • Opaganib, a new chemical entity, is a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor, with suggested dual anti-inflammatory and antiviral activity.
  • Opaganib is host-targeted and, based on data accumulated to date, is expected to maintain effect against emerging viral variants, having already shown in vitro inhibition against variants of concern, including Omicron and Delta.
  • All forward-looking statements included in this press release are made only as of the date of this press release.

RedHill and Kukbo Enter Oral Opaganib License for COVID-19 in South Korea

Retrieved on: 
Tuesday, March 15, 2022
KOSPI, Gastritis, SEC, IL-6, NTM, Ix, Mortality, Cholangiocarcinoma, Opioid, Risk, Authorization, TNF, Annual report, Patient, Review, Partnership, Private Securities Litigation Reform Act, Xi, Nasdaq, Redhill, Crohn's disease, COVID-19, IBS-D, Forward-looking statement, Helicobacter pylori, Korea Disease Control and Prevention Agency, Security (finance), Orphan drug, National Institute, Company, Research, Cancer, CEO, Severe acute respiratory syndrome coronavirus 2, Genta (company), Opaganib, Prostate cancer, Bronchoalveolar lavage, Diarrhea, Feedback, ABC294640, U.S. Securities and Exchange Commission, Delta, MedRxiv, Vii, Marketing, Gastroenteritis, RNA, Pharmaceutical industry, Vaccine

TEL-AVIV, Israel, and RALEIGH, N.C., March 15, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced that it has entered into an exclusive license agreement with Kukbo Co. Ltd. (Kospi: 001140) ("Kukbo"), a South Korean corporation, for oral opaganib[1] for the treatment of COVID-19, in South Korea.

Key Points: 
  • TEL-AVIV, Israel, and RALEIGH, N.C., March 15, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced that it has entered into an exclusive license agreement with Kukbo Co. Ltd. (Kospi: 001140) ("Kukbo"), a South Korean corporation, for oral opaganib[1] for the treatment of COVID-19, in South Korea.
  • Kukbo will receive the exclusive rights to commercialize opaganib in South Korea for COVID-19.
  • Together with our partner, Kukbo, we are working hard to bring opaganib to Korean patients in need of new COVID-19 therapeutic options."
  • "With the data supporting opaganib for COVID-19, and the expanded partnership with RedHill, Kukbo is determined to work with local regulators with the aim of bringing opaganib to South Korean patients, as soon as possible."

RedHill Biopharma to Host Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights Webcast on March 17, 2022

Retrieved on: 
Thursday, March 10, 2022
Nasdaq, Gastroenteritis, EDT, Private Securities Litigation Reform Act, Company, Marketing, Crohn's disease, Research, IBS-D, Diarrhea, U.S. Securities and Exchange Commission, Webcast, Helicobacter pylori, Authorization, Annual report, Cancer, Prostate cancer, ABC294640, TEL, Risk, Ix, Vii, Patient, Feedback, Xi, Redhill, Security (finance), Opioid, COVID-19, Genta (company), Cholangiocarcinoma, Gastritis, SEC, Forward-looking statement, NTM, Pharmaceutical industry, Naloxegol

TEL AVIV, Israel and RALEIGH, NC, March 10, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its fourth quarter and full year 2021 financial results and operational highlights on Thursday, March 17, 2022.

Key Points: 
  • TEL AVIV, Israel and RALEIGH, NC, March 10, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its fourth quarter and full year 2021 financial results and operational highlights on Thursday, March 17, 2022.
  • The Company will host a conference call and webcast on Thursday, March 17, 2022, at 8:30 a.m. EDT, during which it will present key highlights for the fourth quarter and full year of 2021.
  • The webcast including slides will be broadcast live on the Company's website, https://ir.redhillbio.com/events ,and will be available for replay for 30 days.
  • RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases.

RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19

Retrieved on: 
Tuesday, March 1, 2022
Medicare Part D, Helicobacter pylori, Risk, Prostate cancer, Cell, Particle-size distribution, Gastroenteritis, HIV disease progression rates, FSE, Xi, Redhill, Genta (company), SEC, Vii, Gastritis, Feedback, TEL, Security (finance), ABC294640, HPHA, Diarrhea, Annual report, COVID-19, Company, Crohn's disease, Ix, Private Securities Litigation Reform Act, Safety, Disease, Patient, U.S. Securities and Exchange Commission, Trial of the century, IBS-D, Vaccine, Hospital, Severe acute respiratory syndrome coronavirus 2, Protease, NGS, Cholangiocarcinoma, Cancer, Nasdaq, Forward-looking statement, Marketing, NTM, Opioid, Research, Authorization, Pharmaceutical industry, Part

The study met its primary outcome measure, demonstrating a favorable safety and tolerability profile of RHB-107.

Key Points: 
  • The study met its primary outcome measure, demonstrating a favorable safety and tolerability profile of RHB-107.
  • Study arms were well balanced with respect to baseline disease severity, risk factors and vaccination status.
  • RHB-107 is being evaluated in a Phase 2/3 study for treatment of patients with symptomatic COVID-19 who do not require inpatient care.
  • Phase 2/3 study as treatment for symptomatic COVID-19, and targeting multiple other cancer and inflammatory gastrointestinal diseases; (iv) RHB-104, with positive results from a first Phase 3 study for Crohn's disease; (v) RHB-102, with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; and (vi) RHB-106, an encapsulated bowel preparation.

RedHill Biopharma's Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and Corticosteroids in Severe COVID-19

Retrieved on: 
Monday, February 7, 2022
Genta (company), Private Securities Litigation Reform Act, Vii, U.S. Securities and Exchange Commission, National Institute, MHRA, IL-6, Gastroenteritis, Cancer, Opaganib, Safety, SEC, Risk, TEL, Cholangiocarcinoma, Mortality, Xi, RNA, Intubation, Opioid, Research, Company, Delta, Marketing, FDA, MedRxiv, Security (finance), Ix, Diarrhea, Authorization, NASDAQ, Death, Crohn's disease, Redhill, IBS-D, Fraction of inspired oxygen, NTM, Patient, Review, Severe acute respiratory syndrome coronavirus 2, EMA, Pneumonia, Orphan drug, Helicobacter pylori, COVID-19, Prevalence, TNF, ABC294640, Prostate cancer, Bronchoalveolar lavage, Annual report, Nasdaq, SOC, Feedback, Gastritis, Forward-looking statement, Pharmaceutical industry, Vaccine, Omicron, EU

The first analysis showed that opaganib significantly reduced mortality when given to patients who received remdesivir and corticosteroids, the best available standard-of-care (SoC) for hospitalized patients.

Key Points: 
  • The first analysis showed that opaganib significantly reduced mortality when given to patients who received remdesivir and corticosteroids, the best available standard-of-care (SoC) for hospitalized patients.
  • Oral opaganib has now shown an ability to reduce deaths, speed up recovery and clear viral RNA, all with a safety and tolerability profile similar to placebo.
  • "The hospitalized moderate to severe COVID-19 patient group is estimated to represent more than 50% of all hospitalized COVID-19 cases and growing.
  • Oral opaganib was studied in a global Phase 2/3 study in hospitalized patients with severe COVID-19 pneumonia (NCT04467840).

RedHill Biopharma Announces Additional Insider Buying

Retrieved on: 
Wednesday, December 15, 2021
Gastroenteritis, Forward-looking statement, U.S. Securities and Exchange Commission, Company, XV, MAP, IBS-D, Feedback, Private Securities Litigation Reform Act, Gastritis, Authorization, Xi, Nasdaq, Prostate cancer, NTM, Ix, COVID-19, Cancer, Helicobacter pylori, Annual report, Chief executive officer, Risk, SEC, American depositary receipt, Opioid, ABC294640, CEO, Research, Marketing, Patient, Crohn's disease, ADSS, Security (finance), Vii, Cholangiocarcinoma, Redhill, Employment, Diarrhea, Genta (company), Pharmaceutical industry, Naloxegol

RALEIGH, N.C. and TEL-AVIV, Israel, Dec. 15, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that members of its board of directors and senior management, including the Company's Chairman & CEO, Mr. Dror Ben-Asher, collectively purchased approximately an additional 66,000 American Depositary Shares (ADSs) of RedHillsince mid-October, in open-market transactions.

Key Points: 
  • RALEIGH, N.C. and TEL-AVIV, Israel, Dec. 15, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that members of its board of directors and senior management, including the Company's Chairman & CEO, Mr. Dror Ben-Asher, collectively purchased approximately an additional 66,000 American Depositary Shares (ADSs) of RedHillsince mid-October, in open-market transactions.
  • RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases.
  • RedHill promotes the gastrointestinal drugs, Movantik for opioid-induced constipation in adults[1], Taliciafor the treatment of Helicobacter pylori (H. pylori) infection in adults[2], and Aemcolo for the treatment of travelers' diarrhea in adults[3].
  • All forward-looking statements included in this press release are made only as of the date of this press release.

RedHill Biopharma to Host Third Quarter 2021 Financial Results and Operational Highlights Webcast on November 30, 2021

Retrieved on: 
Wednesday, November 24, 2021
Patient, Private Securities Litigation Reform Act, IBS-D, Security (finance), NTM, Prostate cancer, Risk, Crohn's disease, Genta (company), Annual report, Forward-looking statement, Company, Cancer, Xi, Cholangiocarcinoma, SEC, U.S. Securities and Exchange Commission, ABC294640, Authorization, COVID-19, EST, Helicobacter pylori, Nasdaq, Research, Diarrhea, Gastritis, Marketing, XV, MAP, Gastroenteritis, TEL, Opioid, Redhill, Webcast, Ix, Feedback, Employment, Vii, Animal, Pharmaceutical industry

TEL AVIV, Israel and RALEIGH, N.C., Nov. 24, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its third quarter 2021 financial results and operational highlights on Tuesday, November 30, 2021.

Key Points: 
  • TEL AVIV, Israel and RALEIGH, N.C., Nov. 24, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its third quarter 2021 financial results and operational highlights on Tuesday, November 30, 2021.
  • The Company will host a webcast on Tuesday, November 30, 2021, at 8:30 a.m. EST, during which it will present key highlights for the third quarter of 2021.
  • The webcast including slides will be broadcast live on the Company's website, https://ir.redhillbio.com/events , and will be available for replay for 30 days.
  • RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases.

RedHill Biopharma Announces Closing of $15.5 Million Public Offering of American Depositary Shares

Retrieved on: 
Tuesday, November 23, 2021
Patient, Private Securities Litigation Reform Act, Part, IBS-D, Security (finance), Trial of the century, Sale, NTM, Prostate cancer, ADSS, Risk, Crohn's disease, Genta (company), American depositary receipt, Annual report, ADS, 4th floor, Company, Forward-looking statement, Form, Cancer, Xi, Cholangiocarcinoma, SEC, Naloxegol, U.S. Securities and Exchange Commission, ABC294640, Authorization, Park Avenue, Vaccine, COVID-19, Prospectus, Nasdaq, Research, Diarrhea, Gastritis, Medicare Part D, Marketing, Gastroenteritis, SMBC, TEL, Redhill, Ix, Feedback, Vii, Disease, No, Pharmaceutical industry

TEL AVIV, Israel and RALEIGH, N.C., Nov. 23, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of the previously announced underwritten public offering of approximately 4.7 million American Depositary Shares ("ADSs") for gross proceeds of approximately $15.5 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by RedHill.

Key Points: 
  • TEL AVIV, Israel and RALEIGH, N.C., Nov. 23, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of the previously announced underwritten public offering of approximately 4.7 million American Depositary Shares ("ADSs") for gross proceeds of approximately $15.5 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by RedHill.
  • Each ADS represents ten ordinary shares, par value NIS 0.01 per share, of the Company.
  • In addition, RedHill has granted the underwriter a 30-day option to purchase up to approximately an additional 0.7 million ADSs.
  • RedHill intends to use the net proceeds of the offering to fund its commercialization activities, clinical development programs and for acquisitions and general corporate purposes.